vs
Side-by-side financial comparison of AMERISAFE INC (AMSF) and ARDELYX, INC. (ARDX). Click either name above to swap in a different company.
ARDELYX, INC. is the larger business by last-quarter revenue ($94.5M vs $80.1M, roughly 1.2× AMERISAFE INC). AMERISAFE INC runs the higher net margin — 10.2% vs -39.8%, a 50.0% gap on every dollar of revenue. On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs 10.3%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (13.6% CAGR vs 2.8%).
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
AMSF vs ARDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $80.1M | $94.5M |
| Net Profit | $8.1M | $-37.6M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | 10.2% | -39.8% |
| Revenue YoY | 10.3% | 27.5% |
| Net Profit YoY | -9.0% | — |
| EPS (diluted) | $0.43 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $80.1M | $94.5M | ||
| Q4 25 | $81.6M | $125.2M | ||
| Q3 25 | $82.0M | $110.3M | ||
| Q2 25 | $81.1M | $97.7M | ||
| Q1 25 | $72.6M | $74.1M | ||
| Q4 24 | $74.0M | $116.1M | ||
| Q3 24 | $78.7M | $98.2M | ||
| Q2 24 | $75.8M | $73.2M |
| Q1 26 | $8.1M | $-37.6M | ||
| Q4 25 | $10.4M | $-407.0K | ||
| Q3 25 | $13.8M | $-969.0K | ||
| Q2 25 | $14.0M | $-19.1M | ||
| Q1 25 | $8.9M | $-41.1M | ||
| Q4 24 | $13.2M | $4.6M | ||
| Q3 24 | $14.3M | $-809.0K | ||
| Q2 24 | $11.0M | $-16.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 91.3% | ||
| Q3 25 | — | 96.4% | ||
| Q2 25 | — | 87.3% | ||
| Q1 25 | — | 83.4% | ||
| Q4 24 | — | 84.3% | ||
| Q3 24 | — | 84.0% | ||
| Q2 24 | — | 87.1% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 4.1% | ||
| Q3 25 | 21.3% | 4.2% | ||
| Q2 25 | 21.5% | -14.7% | ||
| Q1 25 | 15.5% | -49.0% | ||
| Q4 24 | 22.7% | 7.0% | ||
| Q3 24 | 22.6% | 2.3% | ||
| Q2 24 | 18.1% | -18.6% |
| Q1 26 | 10.2% | -39.8% | ||
| Q4 25 | 12.8% | -0.3% | ||
| Q3 25 | 16.9% | -0.9% | ||
| Q2 25 | 17.2% | -19.5% | ||
| Q1 25 | 12.3% | -55.5% | ||
| Q4 24 | 17.8% | 4.0% | ||
| Q3 24 | 18.2% | -0.8% | ||
| Q2 24 | 14.5% | -22.5% |
| Q1 26 | $0.43 | $-0.15 | ||
| Q4 25 | $0.55 | $-0.01 | ||
| Q3 25 | $0.72 | $0.00 | ||
| Q2 25 | $0.73 | $-0.08 | ||
| Q1 25 | $0.47 | $-0.17 | ||
| Q4 24 | $0.69 | $0.01 | ||
| Q3 24 | $0.75 | $0.00 | ||
| Q2 24 | $0.57 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.2M | $238.1M |
| Total DebtLower is stronger | — | $203.5M |
| Stockholders' EquityBook value | $246.6M | $148.6M |
| Total Assets | — | $504.5M |
| Debt / EquityLower = less leverage | — | 1.37× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $34.2M | $238.1M | ||
| Q4 25 | $61.9M | $68.0M | ||
| Q3 25 | $54.7M | $42.7M | ||
| Q2 25 | $48.5M | $90.0M | ||
| Q1 25 | $44.8M | $30.8M | ||
| Q4 24 | $44.1M | $64.9M | ||
| Q3 24 | $63.7M | $47.4M | ||
| Q2 24 | $30.6M | $41.9M |
| Q1 26 | — | $203.5M | ||
| Q4 25 | — | $202.8M | ||
| Q3 25 | — | $202.1M | ||
| Q2 25 | — | $201.4M | ||
| Q1 25 | — | $151.3M | ||
| Q4 24 | — | $150.9M | ||
| Q3 24 | — | $100.7M | ||
| Q2 24 | — | $100.2M |
| Q1 26 | $246.6M | $148.6M | ||
| Q4 25 | $251.6M | $166.9M | ||
| Q3 25 | $274.8M | $154.3M | ||
| Q2 25 | $265.6M | $139.5M | ||
| Q1 25 | $260.8M | $145.7M | ||
| Q4 24 | $257.3M | $173.3M | ||
| Q3 24 | $314.4M | $158.3M | ||
| Q2 24 | $301.0M | $147.0M |
| Q1 26 | — | $504.5M | ||
| Q4 25 | $1.1B | $501.6M | ||
| Q3 25 | $1.2B | $486.2M | ||
| Q2 25 | $1.2B | $466.8M | ||
| Q1 25 | $1.2B | $410.2M | ||
| Q4 24 | $1.2B | $435.8M | ||
| Q3 24 | $1.3B | $367.9M | ||
| Q2 24 | $1.2B | $343.5M |
| Q1 26 | — | 1.37× | ||
| Q4 25 | — | 1.21× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.44× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMSF
Segment breakdown not available.
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
